PAULA JEAN KAPLAN-LEFKO, Ph.D. Curriculum Vitae PERSONAL HISTORY: Business Address: CURRENT POSITION: Division of Hematology-Oncology 14-627 Factor Building UCLA Medical Center 10833 Le Conte Ave. Los Angeles, CA 90095 Phone: 310-206-2090 Fax: 310-206-2133 Email: pkaplanlefko@mednet.ucla.edu Project Scientist Department of Medicine, Division of Hematology/Oncology UCLA, Los Angeles, CA EDUCATION: 1983-1988 B.A. (Biology) Scripps College, Claremont, CA 1985-1986 Study Abroad Hebrew University, Jerusalem, Israel 1989-1996 Ph.D. (Biology) Tufts University, Medford, MA 1996-2002 Postdoctoral Fellowship Baylor College of Medicine, Houston, TX PROFESSIONAL EXPERIENCE: 1988-1989 Research Technician/Clinical Technician Cytometrics, San Diego, CA 2002-2005 Research Scientist I, Oncology Research Amgen, Inc., Thousand Oaks, CA 2005-2009 Senior Scientist, Oncology Research Amgen, Inc., Thousand Oaks, CA 2009-2011 Principal Scientist, Oncology Research Amgen, Inc., Thousand Oaks, CA Kaplan-Lefko CV 2015 July 2012-April 2013 Visiting Associate Researcher Department of Medicine, Division of Hematology/Oncology UCLA, Los Angeles, CA April 2013-June 2014 Associate Researcher Department of Medicine, Division of Hematology/Oncology UCLA, Los Angeles, CA July 2014 – present Project Scientist Department of Medicine, Division of Hematology/Oncology UCLA, Los Angeles, CA PROFESSIONAL ACTIVITIES: Investigational New Drug (IND) Applications (Trials managing) BB-IND 13859. Adoptive Transfer of MART-1 F5 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) after a Non-myeloablative Conditioning Regimen, with Administration of MART-126-35-Pulsed Dendritic Cells and Interleukin-2, in Patients with Advanced Melanoma. UCLA IRB# 08-02-020/10-001212. Sponsor Ribas. BB-IND 14760. MART-1 F5 TCR Engineered Adoptive Cell Transfer Therapy with CTLA4 Blockade. IRB#12-000164. Sponsor Ribas. BB-IND 15167. Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) after a Nonmyeloablative Conditioning Regimen, with Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients with Advanced Malignancies. IRB#12-000153. Sponsor Ribas. BB-IND 15167. NY-ESO-1TCR Engineered Adoptive Cell Transfer Therapy with CTLA4 Blockade. IRB#13-001624. Sponsor Ribas. IND pending. Studies of Immunogenicity of Intralesional Injection of Talimogene Laherparepvec (T-Vec) in Patients with Melanoma. IRB#pending. Sponsor Ribas. IND pending. Biomarkers of durable response with intermittent therapy with LGX818 and MEK162 combined therapy in patients with BRAF mutant metastatic melanoma. IRB#pending. Sponsor Ribas. IND pending. Adoptive Transfer of MART-1 F5 TCR/sr39TK Engineered Peripheral Blood Mononuclear Cells (PBMC) after a Nonmyeloablative Conditioning Regimen, with Administration of MART-126·35-Pulsed Dendritic 2 Kaplan-Lefko CV 2015 Cells and Interleukin-2, in Patients with Advanced Melanoma. IRB # pending. Sponsor Ribas. Pre-IND. Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Hematopoietic Stem Cells (HSC) after a Nonmyeloablative Conditioning Regimen, with Administration of Interleukin2, in Patients with Advanced Malignancies. Sponsor Ribas. Preclinical Toxicology Protocols Written in Support of Future Clinical Trial (Pre-IND) Title: Effects of Co-Administration of NY-ESO-1 TCR genetically modified T cells and HSCs in HLA-A2.1/Kb mice; Role: Project Manager Title: In Vivo Assessment of Suicide Gene Function of sr39TK Transgene in RRL-MSCVoptNYESOoptsr39TK Lentiviral Vector Transduced Human HSPCs Title: In Vitro Assessment of the Insertional Immortalization Activity of the NY-ESO1 TCR/sr39TK Lentiviral Vector; Role: Project Manager Title: Assessment of Immunogenicity of Administration of NY-ESO-1 TCR/sr39TK genetically modified HSCs in HLA-A2.1/Kb Mice; Role: Project Manager Title: In Vivo Assessment of the Insertion Profile of the NY-ESO1 TCR/sr39TK Lentiviral Vector; Role: Project Manager Teaching Experience Fall 1989, 1991, 1993 Graduate Teaching Assistant in Introductory Biology course and laboratory, Tufts University, Department of Biology, Medford, MA Spring 1990 Graduate Teaching Assistant in Experiments in Biology laboratory, Tufts University, Department of Biology, Medford, MA Fall 1990 Graduate Teaching Assistant in Genetics course and laboratory, Tufts University, Department of Biology, Medford, MA Spring 1991 Graduate Teaching Assistant in Microbiology laboratory, Tufts University, Department of Biology, Medford, MA Spring 1993 Graduate Teaching Assistant in Endocrinology, University, Department of Biology, Medford, MA 3 Tufts Kaplan-Lefko CV 2015 2001 Teaching Assistant at the Techniques for Modeling Human Cancer in Mice Workshop, The Jackson Laboratory, Bar Harbor, ME Mentoring/Supervising (Limited to UCLA) 2012 Aida Attar, Graduate Student, UCLA 2013 Steven Blum, Medical Student, UCLA Zeynep Eroglu, Oncology Fellow, UCLA/City of Hope Daniel Shin, Oncology Fellow, UCLA Tiffany Moalemzadeh, Milken Community High School Student Angel Garcia Diaz, Post-doctoral Fellow, UCLA 2014 Tiffany Moalemzadeh, Milken Community High School Student Overseeing the following people in regulatory work related to clinical trials: Zeynep Eroglu, Oncology Fellow, UCLA/City of Hope Daniel Shin, Oncology Fellow, UCLA Andrea Hobby, Regulatory Coordinator, UCLA Leading CIRM Disease Team Grant Group. Overseeing the following people in studies to obtain FDA approval for our proposed use of T cell receptor engineered hematopoietic stem cells: Angel Garcia Diaz, Post-doctoral Fellow, UCLA Giulia Parisi, Post-doctoral Fellow, UCLA Cristina Puig Saus, Post-doctoral Fellow, UCLA Paige Krystofinski, Staff Research Associate, UCLA Ruixue Zhang, Staff Research Associate, UCLA Overseeing the following people in the manufacturing of clinical grade gene modified cells: Beata Berent Maoz, Project Scientist, UCLA Rongqing Guo, Staff Research Associate, UCLA Jia Pang, Staff Research Associate, UCLA 2015 Sofia Martinez, Volunteer, UCLA 4 Kaplan-Lefko CV 2015 Community Service 1991 Organized the Department of Biology seminar series, Tufts University, Medford, MA 1991-1993 Group leader for the teaching assistant orientation, Tufts University, Medford, MA 1992-1994 Dept. of Biology representative to the Graduate Student Council, Tufts University, Medford, MA 1992-1994 Dept. of Biology graduate student orientation committee, Tufts University, Medford, MA 1997-2002 Baylor College of Medicine Postdoctoral Association member, Houston, TX 2000-2001 Participant, Steinberg Leadership Institute, Anti-Defamation League, Houston, TX 2004 Participated in an elementary school career day, Los Angeles, CA 2007 Presented at the Amgen new hire orientation, Thousand Oaks, CA 2007 Panel member representing Amgen in 2 High School Science and Technology Showcases, Westlake Village and Newbury Park, CA 2009, 2008 Discussion leader and panelist in the Amgen Scholar Program, UCLA, Los Angeles, CA 2012 Contributed articles to the Southern California American Medical Writers Association (AMWA) chapter newsletter 2012-present Electronic case report form (eCRF) development committee for investigator-initiated clinical trials, UCLA 2015-present Member of the Institutional Biosafety Committee (IBC) Faculty/Researcher Advisory Committee, UCLA Professional Associations 1992-present Women in Cancer Research 5 Kaplan-Lefko CV 2015 1992-present American Association for Cancer Research 1997-2002 Society for Basic Urologic Research 1998-2002 IGF Society 1998-2002 Endocrine Society 2011-present American Medical Writers Association Editorial Services 2000-2002 Reviewer for Urology 2000-2002 Reviewer for The Journal of Urology 2005 Reviewer for Clinical Cancer Research 2005 Reviewer for Journal of Biological Chemistry 2007 Reviewer for Cancer Research 2007 Reviewer for Molecular Therapeutics 2007 Reviewer for Gynecologic Oncology Patents May 5, 2011 Teresa Burgess, Angela Kaplan-Lefko, Anthony Combinations VEGF (R) Factor (c-Met) Inhibitors 2011/0104161 A1. Coxon, Isabelle Dussault, Paula Polverino and Darrin Beaupre. Inhibitors and Hepatocyte Growth for the Treatment of Cancer. US HONOR AND SPECIAL AWARDS 1992 International Symposium on Biology of Prostate Growth, Travel Award 1993, 1989-1991 Teaching Fellowship, Tufts University, Medford, MA 1994, 1993 Graduate School of Arts and Science, Travel Award, Medford, MA 1994-1996, 1992 Research Fellowship, Tufts University, Medford, MA 6 Kaplan-Lefko CV 2015 1997, 1995, 1993 Gordon Research Conference on Hormonal Carcinogenesis, Travel Award 1998 AACR Molecular Biology of Neoplasia Workshop, Participant 1999 International Symposium on Insulin-like Growth Factors, Travel Award RESEARCH GRANTS AND FELLOWSHIPS RECEIVED 1997-2000 National Cancer Institute, National Research Service Award, CA74589. Title: IGF in Prostate Cancer: A Transgenic Study. Principle Investigator. $93,948 1999-2004 National Institutes of Health, Biochemical Endocrinology Study Section, R01, CA82807. Title: IGF Axis in Prostate Cancer: A Transgenic Study. Co-authored with postdoc advisor, Norman Greenberg. $1,335,180 2000-2003 Association for the Cure of Cancer of the Prostate (CaP CURE), Young Investigator Award. Title: Abrogation of IGF1R as Therapy for Prostate Cancer. Principle Investigator. $150,000 LECTURES AND PRESENTATIONS Spring 1993, 1992 Tufts University, Department of Biology, Medford, MA Howard Hughes Foundation Teaching Scholar Program; Prepared and presented lectures in Endocrinology 110 on the topics of peptide hormone action, growth factors, male reproduction and sex differentiation under the guidance of department faculty Spring 1995, 1994, 1993 Tufts University, Department of Biology, Medford, MA Guest lecturer for Endocrinology 110; Title: Peptide hormone action 1995 Harvard University, Department of Urology, Children’s Hospital, Boston, MA; Title: Involvement of the EGF family in hormonally induced prostatic dysplasia 1999 MD Anderson Cancer Center, Houston, Genitourinary Oncology Seminar Series; Title: IGF axis in prostate cancer 7 TX. The Kaplan-Lefko CV 2015 1999 Baylor College of Medicine, Department of Cell Biology Reproduction & Development Workshop, Houston, TX; Title: The IGF axis in prostate cancer 1999 MD Anderson Cancer Center, Houston, TX. Thoracic/Head and Neck Medical Oncology Seminar Series; Title: The IGF axis in prostate cancer 1999 MD Anderson Cancer Center, Division of Cancer Prevention Seminar Series, Houston, TX. Title: Changes in the insulin-like growth factor axis in prostate cancer using transgenic animal models 2000 Baylor College of Medicine, Urology Grand Rounds, Houston, TX. Title: Insulin-like growth factor axis in prostate cancer 2007 University of California at Santa Barbara, Guest lecturer for Pharmacology course. Title: The Use of Preclinical Models in Drug Development 2014 University of Southern California, Guest lecturer for RSCI606 Regulation of Emerging Technologies and Biological Products. Title: Gene Therapy: Regulations and Current Status 8 Kaplan-Lefko CV 2015 RESEARCH PAPERS PEER-REVIEWED (PUBLISHED) 1. Ghatak, S, Oliveria, P, Kaplan, P and Ho, S-M. 1996. Expression and regulation of metallothionein mRNA levels in the prostates of Noble rats: Lack of expression in the ventral prostate and regulation by sex hormones in the dorsolateral prostate. The Prostate. 29:91-100. 2. Kaplan, PJ, Leav, I, Greenwood, J, Kwon, PWL and Ho, S-M. 1996. Involvement of transforming growth factor α (TGFα) and epidermal growth factor receptor (EGFR) in sex hormone-induced prostatic dysplasia and the growth of an androgen-independent transplantable carcinoma of the prostate. Carcinogenesis. 17:2571-2579. 3. Foster, BA, Kaplan, PJ and Greenberg, NM. 1999. Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model. Prostate Cancer and Prostatic Diseases. 2:76-82. 4. Kaplan, PJ, Mohan, S, Cohen, P, Foster, BA and Greenberg, NM. 1999. The IGF axis and prostate cancer: Lessons from TRAMP. Cancer Research. 59:2203-2209. 5. Foster, BA, Evangelou, A, Gingrich, JR, Kaplan, PJ, DeMayo, F and Greenberg, NM. 2002. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation. 70(9-10):624-632. 6. Uzgare, AR, Kaplan, PJ and Greenberg, NM. 2003. Differential expression and activation of p38 MAPK, Erk 1/2 and Jnk during the initiation and progression of prostate cancer. Prostate. 55(2):128-139. 7. Kaplan-Lefko, PJ, Chen, TM, Maddison, LA, Huss, WJ, Barrios, R, Ittman, M, Ayala, G and Greenberg, NM. 2003. Pathobiology of autochthonous prostate cancer in a transgenic mouse model. Prostate. 55(3):219-237. 8. Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, Bismar TA, Pollak M. 2005. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene. 24:4736-40. 9. Morgenbesser SD, McLaren RP, Richards B, Zhang M, Akmaev VR, Winter SF, Mineva ND, Kaplan-Lefko PJ, Foster BA, Cook BP, Dufault MR, Cao X, Wang CJ, Teicher BA, Klinger KW, Greenberg NM, Madden SL. 2007. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. Prostate. 67:83-106. 10. Kaplan-Lefko PJ, Sutherland BW, Evangelou AI, Hadsell DL, Barrios RJ, Foster BA, DeMayo F and Greenberg NM. 2008. Enforced epithelial expression of IGF-1 causes 9 Kaplan-Lefko CV 2015 hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis. Oncogene. 27:2868-76. 11. Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I. 2008. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 283:2675-83. 12. Albrecht BK, Harmange JC, Bauer D, Berry L, Bode C, Boezio AA, Chen A, Choquette D, Dussault I, Fridrich C, Hirai S, Hoffman D, Larrow JF, Kaplan-Lefko P, Lin J, Lohman J, Long AM, Moriguchi J, O’Connor A, Potashman MH, Reese M, Rex K, Siegmund A, Shah K, Shimanovich R, Springer SK, Teffera Y, Yang Y, Zhang Y and Bellon SF. 2008. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the cMet kinase. J Med Chem. 51:2879-82. 13. Sutherland BW, Knoblaugh SE, Kaplan-Lefko PJ, Wang F, Holzenberger M and Greenberg NM. 2008. Conditional deletion of IGF1R in prostate epithelium. Cancer Res. 68:3495-3504. 14. Liu L, Siegmund A, Xi N, Kaplan-Lefko P, Rex K, Chen A, Lin J, Moriguchi J, Berry L, Huang L, Teffera Y, Yang Y, Zhang Y, Bellon SF, Lee M, Shimanovich R, Bak A, Dominguez C, Norman MH, Harmange JC, Dussault I and Kim TS. 2008. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: AMG 458. J Med Chem. 51:368891. 15. Zhang Y, Kaplan-Lefko PJ, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B, Coxon A, Reese M, Kim TS, Lin J, Chen A, Burgess TL and Dussault I. 2008. Identification of a novel recepteur d’origine nantais/c-Met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res. 68:6680-6687. 16. D’Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I, Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I and Kim TS. 2008. Design, synthesis, and biological evaluation of potent c-Met inhibitors. J. Med. Chem. 51:5766-5779. 17. Boezio AA, Berry L, Albrecht BK, Bauer D, Bellon SF, Bode C, Chen A, Choquette D, Dussault I, Fang M, Hirai S, Kaplan-Lefko P, Larrow JF, Lin MH, Lohman J, Potashman MH, Qu Y, Rex K, Santostefano M, Shah K, Shimanovich R, Springer SK, Teffera Y, Yang Y, Zhang Y, Harmange JC. 2009. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg Med Chem Lett. 19:6307-12. 18. Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M and Gore L. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a 10 Kaplan-Lefko CV 2015 fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. 2010. Clin Cancer Res. 16:699-710. 19. Zoog SJ, Ma CY, Kaplan-Lefko PJ, Hawkins JM, Moriguchi J, Zhou L, Pan Y, Hsu CP, Friberg G, Herbst R, Hill J and Juan G. 2010. Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling. Cytometry A. 77:849-60. 20. Kaplan-Lefko PJ, Graves JD, Zoog SJ, Pan Y, Wall J, Branstetter DG, Moriguchi J, Coxon A, Huard JN, Xu R, Peach ML, Juan G, Kaufman S, Chen Q, Bianchi A, Kordich JJ, Ma M, Foltz IN and Gliniak BC. 2010. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 9:618-31. 21. Rossin R, Kohno T, Hagooly A, Sharp T, Gliniak B, Arroll T, Chen Q, Hewig A, Kaplan-Lefko P, Friberg G, Radinsky R, Evelhoch JL, Welch MJ, Hwang DR. 2011. Characterization of 64Cu-DOTA-conatumumab: a PET tracer for in vivo imaging of death receptor 5. J Nucl Med. 52:942-9. 22. Chodon T, Comin-Anduix B, Chmielowski B, Koya K, Wu Z, Allen-Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel T, Ishiyama A, Czernin J, Radu C, Wang X, Gjertson D, Cochran A, Cornetta K, Wong D, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen P, Daniels G, Mukherji B, Yang L, Zack J, Kohn D, Heath J, Glaspy J, Witte O, Baltimore D, Economou J and Ribas A. 2014. Adoptive transfer of MART-1 T cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 20:2457-65. 23. Payton M, Jun H, Wayne W, Yu D, Manoukian R, Chung G, Zhang L, Sun J-R, KaplanLefko P, Radinsky R, Kendall R, Oliner J and Coxon A. 2014. Antagonism of angiopoietinTie2 and Dll4-Notch signaling mediate distinct and opposing effects on tumor-associated endothelial cell proliferation. Lab Invest. 94: 12-96-1308. RESEARCH PAPERS – PEER REVIEWED (IN PRESS) None RESEARCH PAPERS – PEER REVIEWED (SUBMITTED) None RESEARCH PAPERS – NON-PEER-REVIEWED None CHAPTERS None 11 Kaplan-Lefko CV 2015 LETTERS TO THE EDITOR None REVIEWS 1. Foster, B.A., Kaplan, P.J. and Greenberg, N.M. 1999. Peptide growth factors and prostate cancer: New models, new opportunities. Cancer and Metastasis Reviews. 17:317324. 2. Dussault I, Kaplan-Lefko P, Jun T, Coxon A, Burgess TL. 2006. HGF- and c-Mettargeted drugs: hopes, challenges and their future in cancer therapy. Drugs of the Future. 31:819-825. 3. Jun HT, Stevens J and Kaplan-Lefko P. 2008. Top NOTCH Targets: Notch Signaling in Cancer. Drug Development Research. 69:319-328. EDITORIALS None PAPERS IN PREPARATION None ABSTRACTS 1. Kaplan, P. and Ho, S-M. 1992. A possible role of EGFR in mediating a steroid-induced prostatic dysplasia. International Symposium on Biology of Prostate Growth, Bethesda, MD. 2. Kaplan, P. and Ho, S-M. 1993. Possible involvement of TGFα and its receptor in the progression of a hormonally induced adenocarcinoma in the rat dorsolateral prostate. Gordon Research Conference on Hormonal Carcinogenesis, Newport, RI. 3. Kaplan, P., Montana, J., and Ho, S-M. 1994. Involvement of the TGFα/EGF receptor in the induction and development of prostatic dysplasia and carcinoma in Noble rats treated with testosterone and estradiol. American Association for Cancer Research Annual Meeting. 35, abstract # 1561, p. 261. 4. Kaplan, P., Greenwood, J., Montana, J. and Ho, S-M. 1994. Activation of the transforming growth factor alpha/epidermal growth factor receptor signal transduction pathway in precancerous and cancerous rat prostatic tissues. New England Endocrinology Conference, Durham, NH. 12 Kaplan-Lefko CV 2015 5. Kaplan, P., Montana, J. and Ho, S-M. 1995. Enhanced expression of TGFα and EGF receptor in rat prostatic dysplasia and carcinoma. American Association for Cancer Research Annual Meeting. 36, abstract #1594, p. 267. 6. Kaplan, P., Hadsell, D., DeMayo, F., Rosen, J. and Greenberg, N. 1997. Deregulated IGF expression in the prostate of transgenic mice. American Association for Cancer Research Annual Meeting. 38, abstract #2813, p. 420. 7. Kaplan, P., Hadsell, D., DeMayo, F., Rosen, J. and Greenberg, N. 1997. Deregulated IGF expression in the prostate of transgenic mice. Gordon Research Conference on Hormonal Carcinogenesis, Tilton, NH. 8. Kaplan, P., Hadsell, D.L., Rosen, J.M. and Greenberg, N.M. 1997. Transgenic deregulation of IGF expression in the prostate. M.D. Anderson Symposium on Fundamental Cancer Research, Houston, TX. 9. Kaplan, P. and Greenberg, N.M. 1998. IGF expression during prostate cancer progression in TRAMP mice. American Association for Cancer Research Annual Meeting. 39, abstract #749, New Orleans, LA. 10. Kaplan, P.J., Hadsell, D.L., Rosen, J.M. and Greenberg, N.M. 1998. Deregulated IGF expression is associated with prostate cancer progression in transgenic mice. Molecular Biology and Pathology of Neoplasia Workshop, American Association for Cancer Research, Keystone, Co. 11. Kaplan, P.J., Huss, W.J., Hadsell, D.L., Rosen, J.M. and Greenberg, N.M. 1999. Expression of prostatic DES-Insulin-like-growth factor I results in preneoplastic changes in transgenic mice. Growth Hormone and IGF Research. 9, abstract #193, International Symposium on Insulin-like Growth Factors, Brighton, England. 12. Kaplan, P., Barrios, R., Hadsell, D., Huss, W., Rosen, J. and Greenberg, N. 2000. Deregulated IGF-I expression in the prostate of transgenic mice contributes to preneoplastic changes. Society for Basic Urologic Research Fall Symposium, Ft. Myers, FL. 13. Kaplan, P., Barrios, R., Hadsell, D., Huss, W., Rosen, J. and Greenberg, N. 2000. Deregulated IGF-I expression in the prostate of transgenic mice contributes to preneoplastic changes. Mouse Models of Cancer, American Association for Cancer Research, La Jolla, CA. 14. Choquette D, Harmange J-C, Kim T-S, Roveto P, Bellon S, Dussault I, Lin J, KaplanLefko P and Rex K. 2007. Pyridones: A new class of orally bioavailable and selective cMet inhibitors. Gordon Research Conference, Medicinal Chemistry. 15. Zhang Y, Kaplan-Lefko P, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B, Coxon A, Burgess TL and Dussault I. 2007. Identification and characterization of a novel RON/c- 13 Kaplan-Lefko CV 2015 Met small molecule inhibitor. Molecular Targets and Cancer Therapeutics AACR-NCIEORTC International Conference, San Francisco, CA. 16. Bellon S, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson C, Coxon A, Kim T-S, Tasker A, Burgess TL and Dussault I. 2007. C-Met inhibitors with novel binding mode show activity against several HPRCC-related mutations. American Association for Cancer Research Annual Meeting, Los Angeles, CA. 17. Kaplan-Lefko P, Gan Y, Huard J, Colloton M, Zoog S, Juan G, Dobson T, Peach M, Pan Y, Kaufman S, Branstetter D, Coxon A, Bianchi A, Wong-Madden S, Foltz I and Gliniak B. 2007. AMG 655, a fully human agonistic antibody against TRAIL receptor-2, induces apoptosis via caspase activation in vitro and in vivo. American Association for Cancer Research Annual Meeting, Los Angeles, CA. 18. Bauer D, Albrecht B, Bellon S, Berry L, Bode C, Boezio A, Chen A, Choquette D, Dussault I, Fridrich C, Hirai S, Larrow J, Kaplan-Lefko P, Lin J, Lohman J, Long A, Moriguchi J, O’Connor A, Potashman M, Reese M, Rex K, Siegmund A, Shah K, Shimanovitch R, Springer S, Teffera Y, Yang Y, Zhang Y and Harmange JC. 2008. Discovery and optimization of a new series of potent and selective inhibitors of the c-Met kinase. American Association for Cancer Research Annual Meeting, San Diego, CA. 19. Hagooly A, Rossin R, Kohno H, Gliniak B, Arroll T, Kaplan-Lefko P, Evelhoch J, Welch M and Hwang D-R. 2008. Measuring DR5 occupancy in tumors using Cu64-DOTAAMG 655. SNM Annual Meeting, New Orleans, LA. 20. Hwang D-R, Rossin R, Gliniak B, Kohno H, Arroll T, Kaplan-Lefko P, Wiezorek J, Friberg G, Radinsky R, Evelhoch JL and Welch MJ. 2008. PET measurement of DR5 receptor occupancy using Cu64-labelled AMG 655 in Colo 205 xenografts. American Association for Cancer Research Annual Meeting, San Diego, CA. 21. Kaplan-Lefko P, Bush T, Belmontes B, Moriguchi J, Dansey M, Osgood T, Canon J, Van Der Vuurst De Vries A-R, Graves J, Branstetter D, Coxon A and Gliniak B. 2008. AMG 655, a fully human agonist antibody against death receptor 5, enhances the anti-tumor activity of gemcitabine in MiaPaCa2/T2, a pancreatic cancer model. American Association for Cancer Research Annual Meeting, San Diego, CA. 22. Connie Ma, Paula Kaplan-Lefko, Jenn Hawkins, Yang Pan, Matt Peach, Scott Patterson, John Ferbas, Greg Friberg, John Hill, Gloria Juan, Stephen Zoog. 2009. Using Fine Needle Aspirates to Quantitate Caspase-3 Activation in Tumors. AAPS National Biotechnology Conference. 23. Kaplan-Lefko P*, Rex K*, Zhang Y, Yang Y, Kha H, Ziegler B, Moriguchi J, Mallari M, Zhao X, Choquette D, Lewis, R Lin J, Shimanovich R, Broome M and Dussault I. 2011. In Vitro and In Vivo Profiling of Class I and Class II ATP-Competitive c-Met Kinase Inhibitors Defines Potential c-Met-Specific Sensitivity Biomarkers. American Association for Cancer Resaerch Annual Meeting, Orlando, FL. *Contributed equally 14 Kaplan-Lefko CV 2015 24. Coxon A, Kaplan-Lefko P, Kaufman S, Moriguchi J, Sun J, Ziegler B, Wayne W, Estrada J, Lavallee J, Park C, Arora T, Burgess T and Jun T. 2012. Inhibition of angiopoietin and Dll4 signaling in the tumor vasculature leads to increased efficacy in mouse tumor xenograft models. American Association for Cancer Research Annual Meeting, Chicago, IL. 25. Bready JV, Kaplan-Lefko P, Moriguchi J, Payton M, Kaufman S, Oliner J, Radinsky R and Coxon A. 2013. Combined treatment of trebananib (AMG 386) with panitumumab in preclinical tumor models. American Association for Cancer Research Annual Meeting, Washington, DC. 26. Hughes PE, Yang Y, Rex K, Zhang Y, Kaplan-Lefko PJ, Caenepeel S, Moriguchi J, Broome M, Choquette D, Radinsky R, Kendall R, Coxon A and Dussault I. 2014. AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models. American Association for Cancer Research Annual Meeting, San Diego, CA. ORAL PRESENTATIONS (Short talks at meetings) 1. Kaplan, P. and Ho, S-M. 1991. The role of growth factors in hormonally induced prostatic dysplasia. New England Endocrinology Conference, Boston, MA 2. Kaplan, P.J., Mohan, S., Cohen, P., Hadsell, D.L., Rosen, J.M. and Greenberg, N.M. 1998. Deregulation of IGF-I contributes to progression prostate cancer while loss of IGF1R is associated with metastatic and androgen independent disease. New Research Approaches in the Prevention and Cure of Prostate Cancer, American Association for Cancer Research, Indian Wells, CA. 3. Kaplan, P.J., Huss, W.J., Hadsell, D.L., Rosen, J.M. and Greenberg, N.M. 1999. Deregulated prostatic IGF-I expression contributes to prostatic neoplasia in transgenic mice. American Association for Cancer Research Annual Meeting. 40, abstract #2683, Philadelphia, PA. 4. Kaplan, P.J., Barrios, R., Hadsell, D.L. and Greenberg, N.M. 2001. Deregulated IGF-I expression in the prostate of transgenic mice exacerbates preneoplastic changes associated with aging. Modeling Human Prostate Cancer in Mice Conference. The Jackson Laboratory, Bar Harbor, ME. 5. Kaplan-Lefko, PJ. 2007. Animal Model Selection for Efficacy with Biologics for Cancer. Biosafe General Membership Meeting, San Diego, CA. 6. Kaplan-Lefko P, Rex K, Moriguchi J, Yang Y, Zhang Y, Chen A, Lin J, Kaufman S, Kim T-S, Liu L, Siegmund A, Harmange JC, Shimanovich R, Burgess T, Kendall R, Radinsky R, Coxon A and Dussault I. 2008. AMG 458, a potent small molecule c- Met inhibitor, has 15 Kaplan-Lefko CV 2015 significant anti-tumor activity in vivo. American Association for Cancer Research Annual Meeting, San Diego, CA. 16